Nitroimidazole drug hapten and holoantigen as well as preparation method and application of nitroimidazole drug hapten and holoantigen

Through the preparation of nitroimidazole drugs hapten and total antigen, combined with monoclonal antibodies, the problem of low efficiency and high cost of detection of nitroimidazole drugs in poultry and egg products is solved, and fast, low cost and high pass are achieved. The quantity test meets the testing requirements of national standards.

CN119019373AActive Publication Date: 2024-11-26SHENZHEN BIOEASY BIOTECHNOLOGY CO LTD +2
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411121645.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

The prior art is used for the detection of nitroimidazole drugs in poultry eggs and egg products in low efficiency and high cost, and requires large equipment and professional technical personnel, making it difficult to meet the fast, low cost and high throughput testing needs.

Method used

The preparation method of nitroimidazole drug haptens and whole antigen is synthesized by the nucleophilic substitution reaction of 2-methyl-5-nitroimidazole and 4-bromo-n-butyne, combined with the click reaction of ethyl azide acetate. Nitroimidazole drug haptens and coupled with carrier protein to form a whole antigen, monoclonal antibodies were prepared for ELISA immunoassay detection.

Benefits of technology

The rapid, low-cost and high-throughput detection of nitroimidazole drugs has been achieved, with the detection limit reaching 1.0μg/kg, which meets national standards and is suitable for preliminary screening and on-site testing of poultry and egg products, reducing the detection time and cost .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019373A_ABST
    Figure CN119019373A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of food safety, in particular to a nitroimidazole drug hapten and holoantigen and a preparation method and application thereof. The preparation method comprises the following steps: taking 2-methyl-5-nitroimidazole as a raw material, carrying out nucleophilic substitution on the 2-methyl-5-nitroimidazole and 4-bromo-n-butyne under an alkaline condition to synthesize an intermediate 1, and carrying out click reaction on the intermediate 1 and ethyl azidoacetate to synthesize an intermediate 2; and hydrolyzing the intermediate 2 under an alkaline condition to synthesize the nitroimidazole drug hapten. On the basis of the hapten, carrier protein is coupled to synthesize holoantigen, the holoantigen can expose a nitroimidazole structure to serve as an antigenic determinant, and the broad-spectrum nitroimidazole drug monoclonal antibody is obtained through screening. The monoclonal antibody provided by the invention is applied to colloidal gold chromatography test paper, a sample treatment scheme of ethyl acetate extraction and sodium chloride salting-out and a colloidal gold chromatography test paper box rapid detection scheme are established, and the monoclonal antibody can be used for rapid screening of nitroimidazole drugs in poultry eggs and egg products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of food safety, and in particular to a nitroimidazole drug hapten and full antigen, and a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] The problem of veterinary drug residues in poultry eggs and egg products is one of the main safety risks of such products, which is mainly related to the use of veterinary drugs beyond the scope and limit in poultry breeding. Nitroimidazole antiprotozoal drugs, including metronidazole, dimenoic acid, hydroxymetronidazole, hydroxydimethylaminobenzoic acid, etc., can be used to treat avian histomoniasis, etc. The large-scale use of this drug will cause it to remain in poultry eggs. After consumers eat poultry eggs containing nitroimidazole drug residues, the drug will accumulate in the human body, thereby affecting the health of consumers. In response to the regulatory requirements for nitroimidazoles in animal foods, relevant countries and organizations have formulated relevant regulations and standards. my country's "National Food Safety Standard Maximum Residue Limits of Veterinary Drugs in Food" (GB 31650-2019) stipulates that metronidazole, dimenoic acid, etc. are allowed for therapeutic use, but must not be detected in animal foods. In order to further monitor the quality and safety of poultry and egg products, since 2021, the national food safety random inspection task will detect nitroimidazole drugs in fresh eggs (hen eggs, duck eggs, quail eggs, goose eggs, pigeon eggs), and in 2023 this indicator will be included in the risk monitoring plan for processed egg products.

[0004] At present, the relevant detection standards for nitroimidazole drugs in poultry eggs and egg products include "National Food Safety Standard Test Method for Nitroimidazole Residues in Animal Food" (GB 31658.23-2022), "Detection of Metronidazole, Dimetridazole and Their Metabolite Residues in Animal Food by Liquid Chromatography-Tandem Mass Spectrometry" (Ministry of Agriculture Announcement No. 1025-2-2008), "Detection Method for Residues of Various Alkaline Drugs in Animal-Derived Foods by Liquid Chromatography-Mass Spectrometry / Mass Spectrometry" (SN / T 2624-2010), etc. The above standard methods all use liquid chromatography-tandem mass spectrometry for determination. Although the detection accuracy can be guaranteed, the detection efficiency is low, including cumbersome pretreatment steps, long experimental cycle, large-scale instruments and equipment and professional technicians are required, and the detection cost is high. Compared with instrumental methods, rapid methods based on immunoassays are fast and easy to operate, do not require large equipment, and have low requirements for operators. They save time and effort, and the detection cost is relatively low. They are fast, low-cost, high-throughput, and highly specific, and are suitable for the preliminary screening and on-site detection of a large number of samples. The design of antigens and the preparation of antibodies are the key to the establishment of immunoassay methods. Therefore, it is particularly important to synthesize nitroimidazole drug haptens that can produce more sensitive antibodies and establish immunoassay methods. Summary of the invention

[0005] In order to overcome the above problems, the present invention provides a nitroimidazole drug hapten and full antigen and a preparation method and application thereof.

[0006] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:

[0007] In the first aspect of the present invention, a nitroimidazole drug hapten is provided, and its structural formula is shown in Formula I:

[0008]

[0009] The second aspect of the present invention provides a method for preparing a nitroimidazole drug hapten, comprising:

[0010] (1) 2-Methyl-5-nitroimidazole and 4-bromobutyne react under alkaline conditions to synthesize intermediate 1 by nucleophilic substitution;

[0011] (2) Intermediate 1 reacts with ethyl azidoacetate to produce a click reaction to synthesize intermediate 2;

[0012] (3) Intermediate 2 is hydrolyzed under alkaline conditions to synthesize nitroimidazole drug hapten;

[0013] The reaction route is:

[0014]

[0015] In one or more embodiments, in step (1), the method for synthesizing intermediate 1 by nucleophilic substitution of 2-methyl-5-nitroimidazole and 4-bromo-n-butyne under alkaline conditions comprises:

[0016] 2-Methyl-5-nitroimidazole, 4-bromobutyne and potassium carbonate were dispersed in N,N-dimethylformamide (DMF) and heated to react to synthesize intermediate 1.

[0017] Preferably, the mass ratio of 2-methyl-5-nitroimidazole, 4-bromo-n-butyne and potassium carbonate is 4.5-5.5:6-7:9-12, preferably 5:6.28:10.87.

[0018] Preferably, the concentration of 2-methyl-5-nitroimidazole in DMF is 45-55 g / L, preferably 50 g / L.

[0019] Preferably, the heating reaction temperature is 65 to 80° C., preferably 70° C., and the reaction time is 20 to 30 h, preferably 24 h.

[0020] In one or more embodiments, in step (2), the method for synthesizing intermediate 2 by the click reaction of intermediate 1 with ethyl azidoacetate comprises:

[0021] Intermediate 1 and ethyl azidoacetate are dispersed in a mixed solution of DMF and water, and then sodium ascorbate and copper sulfate pentahydrate are added as catalysts, and heated to react to synthesize intermediate 2.

[0022] Preferably, the mass ratio of intermediate 1 to ethyl azidoacetate is 7.5-8.5:6.5-8, preferably 8:7.

[0023] Preferably, in the mixed solution of DMF and water, the volume ratio of DMF to water is 30:6-8, preferably 30:7.2.

[0024] Preferably, the concentration of intermediate 1 in the mixed solution of DMF and water is 0.2-0.23 g / L, preferably 0.215 g / L.

[0025] Preferably, the heating reaction temperature is 55 to 70° C., preferably 60° C., and the reaction time is 3 to 5 h, preferably 4 h.

[0026] In one or more embodiments, in step (3), the method for hydrolyzing intermediate 2 under alkaline conditions to synthesize nitroimidazole drug hapten comprises:

[0027] The intermediate is heated in a sodium hydroxide ethanol aqueous solution to react to synthesize a nitroimidazole drug hapten.

[0028] Preferably, the heating reaction temperature is 65 to 80° C., preferably 70° C., and the reaction time is 3 to 5 hours, preferably 4 hours.

[0029] The third aspect of the present invention provides a nitroimidazole drug full antigen, which is obtained by coupling the above-mentioned nitroimidazole drug hapten with a carrier protein.

[0030] In one or more embodiments, the carrier protein includes bovine serum albumin, human serum albumin, chicken ovalbumin or hemocyanin.

[0031] A fourth aspect of the present invention provides a nitroimidazole drug-specific antibody, wherein the antibody is a polyclonal antibody or a monoclonal antibody.

[0032] In one or more embodiments, the nitroimidazole drug-specific antibody is a monoclonal antibody prepared by immunizing experimental animals (such as mice) with the whole antigen of the nitroimidazole drug as an immunogen and an adjuvant.

[0033] The fifth aspect of the present invention provides a nitroimidazole drug detection reagent or kit prepared from a nitroimidazole drug hapten, or a nitroimidazole drug full antigen, or a nitroimidazole drug-specific antibody.

[0034] In one or more embodiments, the nitroimidazole drugs include: metronidazole, dimenidazole, hydroxymetronidazole, and hydroxy dimenidazole.

[0035] The sixth aspect of the present invention provides the use of nitroimidazole drug hapten, or nitroimidazole drug full antigen or nitroimidazole drug specific antibody, or detection reagent or kit in ELISA immunoassay detection of nitroimidazole drugs.

[0036] In one or more embodiments, the ELISA immunoassay method is used to detect the residues of nitroimidazole drugs in the actual sample.

[0037] Preferably, the actual sample includes poultry eggs and egg products.

[0038] The seventh aspect of the present invention provides the use of a nitroimidazole drug hapten, or a nitroimidazole drug full antigen, or a nitroimidazole drug-specific antibody, or a detection reagent in the preparation of a colloidal gold test strip for nitroimidazole drugs.

[0039] Beneficial effects of the present invention:

[0040] (1) In the present invention, 2-methyl-5-nitroimidazole is used as a raw material and reacts with 4-bromo-n-butyne under alkaline conditions to synthesize intermediate 1 by nucleophilic substitution, and intermediate 1 reacts with ethyl azidoacetate to produce a click reaction to synthesize intermediate 2; intermediate 2 is hydrolyzed under alkaline conditions to synthesize a nitroimidazole drug hapten. Based on the hapten, a carrier protein is coupled to synthesize a full antigen, and the full antigen can expose the nitroimidazole structure as an antigenic determinant, and a broad-spectrum nitroimidazole drug monoclonal antibody is screened and obtained.

[0041] (2) The monoclonal antibody provided by the present invention is applied to colloidal gold chromatography test paper, and the colloidal gold chromatography test paper can be used for rapid screening of nitroimidazole drugs in eggs and egg products. The detection limit of the monoclonal antibody is 1.0 μg / kg, which meets the limit requirements of nitroimidazoles in the current national standard "National Food Safety Standard Maximum Residue Limits of Veterinary Drugs in Food" (GB 31650-2019). BRIEF DESCRIPTION OF THE DRAWINGS

[0042] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0043] Figure 1 is a mass spectrometric image of the nitroimidazole hapten represented by formula (I);

[0044] Figure 2 It is the standard curve of indirect competition ELISA for the antibodies of nitroimidazole drugs detected during animal immunization (based on metronidazole);

[0045] Figure 3 Schematic diagram of the structure of the nitroimidazole drug colloidal gold chromatography test paper prepared in Example 4;

[0046] Figure 4 A method for detecting the residue of nitroimidazole drugs in a sample using the nitroimidazole drug colloidal gold chromatography detection device prepared in Example 4, wherein A is the reaction between the sample extract and the nitroimidazole monoclonal antibody-colloidal gold marker; B is the chromatography reaction between the mixed test solution and the nitroimidazole drug colloidal gold chromatography test strip;

[0047] Figure 5 Schematic diagram of the possible results of the nitroimidazole drug chromatography test paper in Example 5. DETAILED DESCRIPTION

[0048] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0049] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0050] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0051] Example 1

[0052] Preparation of nitroimidazole drug haptens:

[0053] (1) 5 g of 2-methyl-5-nitroimidazole, 6.28 g of 4-bromo-n-butyne, 10.87 g of potassium carbonate and 100 mL of DMF were added to a 250 mL clean single-necked bottle in sequence, and the mixture was reacted at 70° C. overnight. After the reaction was completed, the solvent was removed by rotary evaporation, and the intermediate 1 was purified by column chromatography to obtain a transparent crystalline intermediate 1.

[0054] (2) Add intermediate 1 (800 mg), ethyl azidoacetate 700 mg, copper sulfate pentahydrate 180 mg, L-ascorbic acid 250 mg, water 7.2 mL, DMF 30 mL to a 100 mL clean single-mouth bottle, and react at 60°C for 4 h. After TLC detection, the reaction was processed. The reaction solution was added with water, extracted with ethyl acetate twice, and the organic phase was combined and purified by column chromatography to obtain intermediate 2.

[0055] (3) Add intermediate 2 (450 mg), 90 mg of sodium hydroxide, 10 mL of water and 40 mL of ethanol to a 100 mL clean single-mouth bottle in sequence and react at 70°C for 4 h. After TLC detection, the reaction was processed. The pH of the reaction solution was adjusted to neutral, the solvent was evaporated by rotary evaporation, and column chromatography was used for purification to obtain a light yellow powdery solid, which was the nitroimidazole drug hapten. The hapten was identified by mass spectrometry, and the mass spectrum obtained was shown in Figure 1 From the mass spectrum, we can see that the molecular ion peak of the hapten is ESI-[MH] - : 279.24, which is the highest peak, consistent with the molecular weight of the hapten 280.24, indicating that the nitroimidazole hapten shown in formula (I) was successfully synthesized.

[0056] The reaction route is:

[0057]

[0058] Example 2

[0059] Preparation of complete antigen of nitroimidazole drugs:

[0060] Weigh 50 mg of nitroimidazole drug hapten, dissolve in 2.5 mL of DMF, add 25 mg of N-hydroxysuccinimide (NHS), 30 mg of 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCL), react at room temperature for 6 hours to prepare an activation solution; take 45 mg of bovine serum albumin (BSA) and dissolve in 3 mL of 0.1 M boric acid buffer with a pH of 9.0, add 1 mL of DMF, 0.6 mL of the above activation solution, react at room temperature for 4 hours, and then dialyze with PBS (0.01 mol / L, pH=7.4 phosphate buffer), change the solution once every 4 hours, change the solution 7 to 8 times, centrifuge at 4000 rpm for 5 minutes after dialysis, take the supernatant, prepare the nitroimidazole drug full antigen, that is, nitroimidazole hapten-BSA conjugate, and store it at -20°C.

[0061] Example 3

[0062] (1) Animal immunization

[0063] Healthy 6-8 week old BALB / c mice were selected for immunization. The complete nitroimidazole drug antigen obtained in Example 2 was mixed and emulsified with an equal amount of Freund's adjuvant, and then the BALB / c mice were immunized by multiple subcutaneous injections on the back of the neck (except for sprint immunization). Complete Freund's adjuvant was used for the first immunization, with a dose of 180 μg / mouse; after a lapse of 4 weeks, a booster immunization was performed at a dose of 90 μg / mouse, mixed and emulsified with incomplete Freund's adjuvant, and the intervals between subsequent booster immunizations were 3 weeks; for sprint immunization, the dose was halved to 45 μg / mouse, and the complete antigen was diluted with physiological saline and injected intraperitoneally into the mice. After the third immunization of the mice, blood samples were collected by tail cutting, and the titer and IC of the mouse serum were detected by indirect competitive enzyme-linked immunosorbent assay (ic-ELISA). 50 , select high titer, IC 50 Low mice were fused;

[0064] The standard curve of the antibody indirect competition ELISA for detecting nitroimidazole drugs (based on metronidazole) is as follows Figure 2 As shown, from Figure 2 It can be seen that the IC value of nitroimidazole for the detection of nitroimidazole antibody is 50 The value was 2.81 ng / mL, and the detection limit LOD (IC 10 ) was 0.27 ng / mL, and the linear range (IC 20 ~IC 80 ) is 0.97~8.09ng / mL, which can be used to establish a highly sensitive immunoassay method to detect nitroimidazole.

[0065] (2) Cell fusion and cloning

[0066] Spleen cells of immune BALB / c mice were obtained and fused with SP2 / 0 myeloma cells at a quantitative ratio of 10:1 to screen for nitroimidazole monoclonal hybridoma cell lines that stably secreted the full antigen of nitroimidazole drugs;

[0067] (3) Cell cryopreservation and recovery

[0068] Nitroimidazole monoclonal hybridoma cells were prepared into 5×10 6 Cell suspension of 100 cells / mL is stored in liquid nitrogen for a long time. When thawing, take out the cryopreservation tube and immediately put it in a 37℃ water bath to thaw quickly. After centrifugation to remove the cryopreservation solution, transfer it to a culture bottle for culture;

[0069] (4) Preparation and purification of monoclonal antibodies

[0070] Incremental culture method: nitroimidazole monoclonal hybridoma cells are placed in a cell culture medium, cultured at 37°C, and the obtained culture fluid is purified by the caprylic acid-saturated ammonium sulfate method to obtain nitroimidazole drug monoclonal antibodies, which are stored at -20°C. The cell culture medium is RPMI-1640 medium with calf serum and sodium bicarbonate added thereto, so that the mass percentage of calf serum in the cell culture medium is 20%, the mass percentage of sodium bicarbonate in the cell culture medium is 0.2%, and the pH of the cell culture medium is 7.4.

[0071] (5) Preparation of goat anti-mouse antibodies

[0072] The mouse nitroimidazole monoclonal antibody prepared by the above operation was injected into sheep for immune reaction to obtain sheep anti-mouse antibody.

[0073] Example 4

[0074] (1) Preparation of colloidal gold solution

[0075] Dilute the 1% chloroauric acid solution to 0.01% (mass fraction) with double distilled deionized water, take 100mL of 0.01% chloroauric acid solution and place it in a conical flask, heat it to boiling with a constant temperature electromagnetic stirrer, add 2.0mL of 1% trisodium citrate solution under continuous high temperature and continuous stirring, continue to stir and heat at a uniform speed until the solution turns translucent red, stop, cool to room temperature, restore to the original volume with deionized water, and obtain a colloidal gold solution, which is stored at 4°C. The prepared colloidal gold solution is pure, translucent, and free of precipitation and floating matter;

[0076] (2) Preparation of nitroimidazole monoclonal antibody-colloidal gold label

[0077] Under magnetic stirring, adjust the pH value of the colloidal gold solution to 7.2 with 0.2 mol / L potassium carbonate, add the nitroimidazole monoclonal antibody prepared in Example 3 to the colloidal gold solution according to the standard of adding 20-60 μg nitroimidazole monoclonal antibody per milliliter of colloidal gold solution, continue stirring and mixing for 30 minutes, let it stand for 10 minutes, add 10% bovine serum albumin (BSA) solution to make its volume percentage content in the colloidal gold solution 1%, and let it stand for 10 minutes. Centrifuge at 12000 rpm at 4°C for 40 minutes, discard the supernatant, resuspend the precipitate with a resolubilization buffer with a volume of 1 / 10 of the initial colloidal gold solution volume, and prepare the nitroimidazole monoclonal antibody-colloidal gold marker, and store it at 4°C for use;

[0078] Reconstitution buffer: containing 0.3% to 0.5% bovine serum albumin by volume, 0.1% to 0.3% Tween-20 by mass, 3% to 6% trehalose by mass, 0.02 mol / L phosphate buffer with a pH of 7.2;

[0079] (3) Preparation of microwell reaction cup

[0080] Add 100 μL of nitroimidazole monoclonal antibody-colloidal gold marker to the microporous reaction cup, put it into a freeze dryer, pre-freeze it for 3 hours at a cold trap temperature of -50°C, and then vacuum dry it for 6 hours. Then take it out to obtain a microporous reaction cup with freeze-dried nitroimidazole monoclonal antibody-colloidal gold marker, which is sealed and stored. The freeze-dried amount of nitroimidazole monoclonal antibody-colloidal gold marker is 0.20-0.50 μg / mL.

[0081] (4) Preparation of sample pad

[0082] The sample pad was placed in a phosphate buffer containing 0.02 mol / L bovine serum albumin and soaked for 2 hours, and dried at 50°C for 2 hours for later use. The pH of the phosphate buffer was 7.2, and the volume percentage of bovine serum albumin was 1.0%;

[0083] (5) Preparation of reaction membrane

[0084] Coating process: dilute the coating antigen to a concentration of 10 mg / mL with phosphate buffer, and coat it in the detection area (T area) on the nitrocellulose membrane with a gold-labeled gold-spraying membrane instrument, with a coating concentration of 0.5 mg / mL; dilute the goat anti-mouse antibody to a concentration of 10 mg / mL with a phosphate buffer of 0.01 mol / L, pH = 7.4, and coat it in the quality control area (C area) on the nitrocellulose membrane with a gold-labeled gold-spraying membrane instrument, with a coating concentration of 1.0 mg / mL. Dry the coated reaction membrane at 50°C for 6 hours.

[0085] (6) Preparation of nitroimidazole colloidal gold chromatography detection device

[0086] The structure of the test strip is as follows Figure 3 As shown, the sample loading pad, reaction pad and water absorbent pad are sequentially pasted on the bottom plate. Among them, the bottom plate is a PVC bottom plate, the sample loading pad is a filter paper, the water absorbent pad is a filter paper, and the reaction pad is a nitrocellulose membrane. The end of the sample loading pad is connected to the beginning of the reaction pad, the end of the reaction pad is connected to the beginning of the water absorbent pad, the beginning of the sample loading pad is aligned with the beginning of the bottom plate, and the end of the water absorbent pad is aligned with the end of the bottom plate. Obtained. The distance between line C and the end of the sample loading pad is 15.5mm, and the distance between line T and the end of the sample loading pad is 8.5mm; the length of the sample loading pad is 15mm, the length of the reaction pad is 2.5cm, and the length of the water absorbent pad is 43mm.

[0087] The test strips obtained in the above steps are assembled with the microporous reaction cup into a test strip box, which is stored in an environment of 2-8°C and has a shelf life of 12 months.

[0088] Example 5

[0089] The nitroimidazole colloidal gold chromatography detection device prepared in Example 4 was used to detect the residues of nitroimidazole drugs in the sample.

[0090] Take about 500g of the edible part of the sample, mix it evenly with a tissue homogenizer, take about 200g of the prepared sample, put it into clean containers as the sample and the reserved sample, seal it, and mark it. The reserved sample is stored at -18℃. Accurately weigh 5g of the sample (accurate to 0.01g), put it in a 50mL centrifuge tube, add 7mL of ethyl acetate and shake to extract for 5min, add 3g of anhydrous sodium sulfate to the sample, vortex mix it for 1min, and centrifuge it at 4000r / min for 5min, accurately draw 4mL of supernatant into a 10mL centrifuge tube, blow dry it with a sample concentrator at 60℃, add 2mL of n-hexane to completely dissolve it, then add 0.5mL of sample diluent, vortex mix it for 1min, centrifuge it at 4000r / min for 1min, and then draw the lower layer of liquid for detection.

[0091] (2) The test method is as follows: aspirate 200 μL of the test solution into a microwell reaction cup, aspirate until the particles at the bottom of the well are completely dissolved, and incubate at room temperature for 3 minutes. Insert the sample pad end of the test strip vertically downward into the microwell reaction cup and react for 5 minutes at room temperature. The reaction operation process is as follows Figure 4 shown.

[0092] (3) The determination method is as follows: take out the test strip from the microporous reaction cup, discard the sample pad at the bottom of the test strip, and determine the result by comparing the color depth of the control line (C line) and the test line (T line). Figure 5When the control line (C line) does not show color, regardless of whether the test line (T line) shows color, it indicates that the operation is incorrect or the test strip has expired, and the test result is invalid; when the control line (C line) shows color, the test line (T line) does not show color or the color is lighter than the control line (C line), it indicates that the metronidazole content in the sample is higher than the method detection limit, and it is judged as positive; when the control line (C line) shows color, the color of the test line (T line) is darker than the control line (C line) or is basically the same as the control line (C line), it indicates that the metronidazole content in the sample is lower than the method detection limit, and it is judged as negative.

[0093] Example 6

[0094] In order to determine the best method and verify the effect of the method, various parameters and methods are optimized.

[0095] (1) Sample pretreatment and extraction solvent optimization:

[0096] In the existing national standards and industry standards, in order to meet the needs of instrumental analysis, the instrumental analysis pretreatment method for veterinary drug residues in fresh eggs and egg products is mainly organic solvent extraction. In the methods such as "National Food Safety Standard Test Method for Nitroimidazole Drug Residues in Animal Food" (GB 31658.23-2022), "Detection of Metronidazole, Dimetridazole and Their Metabolism Residues in Animal Food by Liquid Chromatography-Tandem Mass Spectrometry" (Ministry of Agriculture Announcement No. 1025-2-2008), "Detection Method for Multiple Basic Drug Residues in Animal Derived Food by Liquid Chromatography-Mass Spectrometry / Mass Spectrometry" (SN / T 2624-2010), solvents such as ethyl acetate are used in the pretreatment process. Considering the specificity of the detection method, the characteristics of the sample matrix, and the convenience of rapid detection operation, this method uses ethyl acetate as the extraction solvent. During the method development and optimization process, the four target substances, metronidazole, dimenidazole, hydroxymetronidazole and hydroxydimetridazole, were tested for their extraction rate by the spike recovery method combined with LC-MS / MS detection. The spike concentration was 5 μg / kg. The extraction rate results are shown in Table 1.

[0097] Table 1 Extraction rate data of each target compound in different matrices

[0098]

[0099] From the data in Table 1, it can be seen that the spiked recovery extraction rates of the four target substances, metronidazole, dimenidazole, hydroxymetronidazole and hydroxy dimenidazole, in different matrices are in the range of 80.6% to 101.7%, showing an ideal extraction rate. The results also meet the recovery rate requirements for this concentration level in the relevant national standards, indicating that ethyl acetate is an ideal extraction solvent.

[0100] (2) Optimization of demulsifier and dehydrator for sample pretreatment

[0101] Egg and egg product matrices are prone to emulsification during pretreatment due to their high protein content. Therefore, it is an important treatment process to use appropriate methods for demulsification, two-phase separation and solvent dehydration. With reference to relevant research literature and standard methods, four dehydrating agents, including saturated sodium chloride solution, sodium chloride, anhydrous sodium sulfate, and sodium chloride + anhydrous sodium sulfate, were selected for optimization testing. The test method is as follows: 5g of egg and egg product samples were weighed and placed in 50mL centrifuge tubes, metronidazole standard was added, mixed and placed for 30min, 7mL of ethyl acetate solvent was added for extraction, vortexed for 5min, and dehydrating agents (3mL, 5mL and 7mL of saturated sodium chloride solution, 1g, 3g, 5g of anhydrous sodium sulfate, 3g, 5g of sodium chloride, and 2g of anhydrous sodium sulfate + 1g of sodium chloride mixed salt) were added and vortexed for 1min, centrifuged at 4000r / min for 5min, and the sample stratification in the centrifuge tube was observed.

[0102] The test results are summarized in Table 2. Saturated sodium chloride solution is commonly used in the pretreatment of veterinary drug residues in meat and meat products. Since the water content of fresh egg matrix is ​​greater than that of meat, the demulsification effect is not achieved after adding saturated sodium chloride solution. Although clear stratification is visible to the naked eye, the supernatant is actually an emulsified layer, which is a colloid after air drying, and the effect is not good. The demulsification effect of using sodium chloride for dehydration is not obvious, and no obvious stratification can occur. After treatment with anhydrous sodium sulfate + sodium chloride (2g + 1g), the mixed solution is obviously stratified, and the supernatant can meet the inspection requirements. The demulsification effect of using anhydrous sodium sulfate alone is obvious, but the supernatant obtained by adding a small amount is less than 4mL, which has a great impact on subsequent analysis; increasing its usage to 3g and 5g found that the demulsification effect is obvious, and the amount of supernatant can meet the subsequent inspection requirements. Considering the ease of operation and detection cost, the present invention determines 3g of anhydrous sodium sulfate as a demulsifying dehydrating agent.

[0103] Table 2 Demulsification and stratification of dehydrating agent

[0104]

[0105] (3) Optimization of the test solution-microwell incubation time

[0106] In order to investigate the effect of the incubation time of the test liquid-microwell on the antigen-antibody reaction, the results of the incubation time of 1min, 3min, 5min, and 7min for egg matrix, duck egg matrix, goose egg matrix, quail egg matrix, marinated egg matrix, salted duck egg matrix, preserved egg matrix, and Songhua egg sausage matrix were studied and compared. The results showed that with the increase of incubation time, the color of the T line and C line of the eight matrix test groups gradually became obvious; when the incubation time was 1min, the color of the T line and C line at the detection limit concentration was similar. With the increase of time, the contrast between the T line and the C line at 3min and above tended to be stable, and the experimental results had good reproducibility and stability. Therefore, the optimal time for the incubation of the test liquid-microwell for all matrices in this method was set to 3min, and the acceptable operation time was within one minute before or after it.

[0107] (4) Optimization of test strip-test solution reaction time

[0108] In order to investigate the effect of the reaction time between the test strip and the test solution on the antigen-antibody reaction, the results of the reaction time of 1min, 3min, 5min and 7min for egg matrix, duck egg matrix, goose egg matrix, quail egg matrix, marinated egg matrix, salted duck egg matrix, preserved egg matrix and Songhua egg sausage matrix were studied and compared. The analysis showed that for all matrices, when the reaction time was 1min and 3min, the color of the T line and C line was lighter, which was not conducive to the interpretation of the results; with the increase of reaction time, the color of the T line and C line gradually became obvious, and the contrast of the T line and C line tended to be stable at 5min and above, the positive and negative of the test strip could be clearly identified, and the color effect was obviously contrasted; within 7min, the positive and negative results were accurately judged and did not change. In order to avoid the influence of long-term placement on the interpretation, the optimal time for the test strip-test solution reaction was set to 5min, and the acceptable operation time was within the first two minutes or the last two minutes.

[0109] (5) Verification of multi-matrix applicability

[0110] The multi-factor method applicability verification was carried out by the spiked test method. The sample matrices selected were chicken eggs, duck eggs, goose eggs, quail eggs, marinated chicken eggs, salted duck eggs, preserved eggs and Songhua egg sausage; the added drugs selected were metronidazole group, demetronidazole group, and metronidazole and demetronidazole 1:1 mixed group; the added concentrations selected were negative matrix, 1.0μg / kg (determination limit), and 2.0μg / kg (double determination limit) three content levels, and the results are shown in Table 3. According to the method of the present invention, the operation test was carried out. The color of the C line in the negative samples of each group was significantly darker than the T line, showing a negative result; the color of the C line in the determination limit samples of each group was darker than the T line, showing a positive result; the color of the C line in the determination limit samples of each matrix was significantly darker than the T line, also showing a positive result. The above results show that the method of the present invention is well applicable to the rapid detection of various nitroimidazole drugs in egg matrix, duck egg matrix, goose egg matrix, quail egg matrix, marinated chicken egg matrix, salted duck egg matrix, preserved egg matrix and Songhua egg sausage matrix, and the sensitivity can fully meet the requirements of the national standard limit (GB 31650), and has strong operability and practical significance.

[0111] Table 3 Consistency verification results of multi-matrix nitroimidazole detection method

[0112]

[0113]

[0114] Compared with the existing laboratory detection method based on liquid chromatography-mass spectrometry to detect the residues of nitroimidazole veterinary drugs such as metronidazole and dexamethasone in animal-derived foods, the method of the present invention has the following advantages for rapid detection of nitroimidazole drugs in eggs and egg products: flexible and convenient site, simple instrument, easy training and operation, low requirements for detection personnel, shortening of detection time by more than 70%, and reducing detection cost by more than 90%.

[0115] Compared with the existing rapid detection methods for veterinary drug residues in eggs and egg products, the present invention can detect high-risk, spot-checked key monitoring items such as metronidazole and dimetronidazole. Compared with the existing rapid detection methods for metronidazole or dimetronidazole, this method can achieve simultaneous detection of multiple residues, greatly improve the efficiency of detection activities, and reduce the economic and time costs of detection; the positive detection limit of this method is consistent with the national standard limit, and has a higher practical promotion value, and the optimized sample pretreatment conditions have higher extraction efficiency and wider matrix applicability.

[0116] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A nitroimidazole drug hapten, characterized in that: Its structural formula is shown in Formula I:

2. The method for preparing the nitroimidazole drug hapten according to claim 1, characterized in that: include: (1) 2-Methyl-5-nitroimidazole and 4-bromobutyne react under alkaline conditions to synthesize intermediate 1 by nucleophilic substitution; (2) Intermediate 1 reacts with ethyl azidoacetate to produce a click reaction to synthesize intermediate 2; (3) Intermediate 2 is hydrolyzed under alkaline conditions to synthesize nitroimidazole drug hapten; The reaction route is:

3. A complete nitroimidazole drug antigen, characterized in that: The nitroimidazole drug hapten according to claim 1 is coupled with a carrier protein to obtain the nitroimidazole drug.

4. The nitroimidazole drug full antigen as claimed in claim 3, characterized in that: The carrier protein includes bovine serum albumin, human serum albumin, chicken ovalbumin or hemocyanin.

5. A nitroimidazole drug-specific antibody, characterized in that: The antibody is a polyclonal antibody or a monoclonal antibody.

6. The nitroimidazole drug-specific antibody according to claim 5, characterized in that: The nitroimidazole drug-specific antibody is a monoclonal antibody prepared by immunizing experimental animals with the whole antigen of the nitroimidazole drug as an immunogen and an adjuvant.

7. A nitroimidazole drug detection reagent or kit prepared using the nitroimidazole drug hapten according to claim 1, the nitroimidazole drug full antigen according to claim 3, or the nitroimidazole drug specific antibody according to claim 5.

8. Use of the nitroimidazole drug hapten according to claim 1, or the nitroimidazole drug full antigen according to claim 3, or the nitroimidazole drug-specific antibody according to claim 5, or the detection reagent or kit according to claim 7 in ELISA immunoassay detection of nitroimidazole drugs.

9. The use according to claim 8, characterized in that ELISA immunoassay was used to detect the residues of nitroimidazole drugs in actual samples; Preferably, the actual sample includes poultry eggs and egg products.

10. Use of the nitroimidazole drug hapten according to claim 1, or the nitroimidazole drug full antigen according to claim 3, or the nitroimidazole drug specific antibody according to claim 5, or the detection reagent according to claim 7 in the preparation of a colloidal gold test strip for nitroimidazole drugs.

Citation Information

Patent Citations

  • Monoclonal antibody, enzyme-linked immunosorbent assay method and kit for detecting nitroimidazoles

    CN104558184A

  • Method for detecting residual quantity of hydroxymetronidazole in food and product

    CN113831290A

  • Hapten for detecting content of dimetridazole and application of hapten

    CN117209481A

  • Metronidazole hapten, artificial antigen and application thereof

    CN117263867A